1. Home
  2. CRSP vs GLOB Comparison

CRSP vs GLOB Comparison

Compare CRSP & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GLOB
  • Stock Information
  • Founded
  • CRSP 2013
  • GLOB 2003
  • Country
  • CRSP Switzerland
  • GLOB Luxembourg
  • Employees
  • CRSP N/A
  • GLOB N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GLOB EDP Services
  • Sector
  • CRSP Health Care
  • GLOB Technology
  • Exchange
  • CRSP Nasdaq
  • GLOB Nasdaq
  • Market Cap
  • CRSP 4.2B
  • GLOB 4.7B
  • IPO Year
  • CRSP 2016
  • GLOB 2014
  • Fundamental
  • Price
  • CRSP $59.12
  • GLOB $92.94
  • Analyst Decision
  • CRSP Buy
  • GLOB Buy
  • Analyst Count
  • CRSP 16
  • GLOB 16
  • Target Price
  • CRSP $71.20
  • GLOB $174.94
  • AVG Volume (30 Days)
  • CRSP 3.5M
  • GLOB 1.1M
  • Earning Date
  • CRSP 08-04-2025
  • GLOB 08-14-2025
  • Dividend Yield
  • CRSP N/A
  • GLOB N/A
  • EPS Growth
  • CRSP N/A
  • GLOB N/A
  • EPS
  • CRSP N/A
  • GLOB 3.38
  • Revenue
  • CRSP $37,675,000.00
  • GLOB $2,455,696,000.00
  • Revenue This Year
  • CRSP $30.25
  • GLOB $4.36
  • Revenue Next Year
  • CRSP $268.62
  • GLOB $6.03
  • P/E Ratio
  • CRSP N/A
  • GLOB $26.89
  • Revenue Growth
  • CRSP N/A
  • GLOB 11.90
  • 52 Week Low
  • CRSP $30.04
  • GLOB $86.02
  • 52 Week High
  • CRSP $63.68
  • GLOB $238.32
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 83.65
  • GLOB 48.42
  • Support Level
  • CRSP $50.26
  • GLOB $89.74
  • Resistance Level
  • CRSP $53.08
  • GLOB $94.59
  • Average True Range (ATR)
  • CRSP 2.78
  • GLOB 2.98
  • MACD
  • CRSP 0.93
  • GLOB 1.12
  • Stochastic Oscillator
  • CRSP 98.13
  • GLOB 98.85

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GLOB Globant S.A.

Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.

Share on Social Networks: